Giverny Capital Inc. Buys 17,650 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Giverny Capital Inc. increased its stake in Medpace Holdings, Inc. by 7.5%, acquiring an additional 17,650 shares during the first quarter.
• Medpace's stock has a current market capitalization of $12.86 billion, with a PE ratio of 34.04 and a one-year high of $501.30.
• Recent analyst ratings show a mix of opinions, with three firms recommending a sell rating, ten a hold, and two a buy, indicating a consensus price target of $406.60.

Giverny Capital Inc. raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 7.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 251,937 shares of the company's stock after buying an additional 17,650 shares during the quarter. Medpace comprises 2.8% of Giverny Capital Inc.'s portfolio, making the stock its 15th largest holding. Giverny Capital Inc. owned approximately 0.88% of Medpace worth $76,763,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brooklyn Investment Group boosted its position in shares of Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after acquiring an additional 71 shares during the period. Whittier Trust Co. boosted its holdings in Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after purchasing an additional 35 shares during the period. Colonial Trust Co SC boosted its holdings in Medpace by 150.0% in the 4th quarter. Colonial Trust Co SC now owns 175 shares of the company's stock valued at $58,000 after purchasing an additional 105 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Medpace during the 1st quarter valued at $60,000. Finally, Assetmark Inc. increased its holdings in shares of Medpace by 24.9% in the first quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after purchasing an additional 43 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Performance

MEDP stock opened at $457.85 on Monday. The company has a market capitalization of $12.86 billion, a PE ratio of 34.04, a price-to-earnings-growth ratio of 2.88 and a beta of 1.42. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $501.30. The company's 50 day moving average price is $362.88 and its two-hundred day moving average price is $331.01.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. The company had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The firm's quarterly revenue was up 14.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.75 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Activity

In other Medpace news, CFO Kevin M. Brady sold 12,000 shares of Medpace stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the transaction, the chief financial officer directly owned 6,000 shares of the company's stock, valued at $2,725,380. The trade was a 66.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of the business's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.14, for a total value of $3,376,050.00. Following the completion of the sale, the vice president owned 57,500 shares of the company's stock, valued at $25,883,050. The trade was a 11.54% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 112,788 shares of company stock valued at $51,018,354. Company insiders own 20.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. UBS Group cut Medpace from a "neutral" rating to a "sell" rating and boosted their target price for the stock from $300.00 to $305.00 in a research report on Tuesday, July 29th. TD Cowen reiterated a "sell" rating and set a $366.00 price target (up previously from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. William Blair reissued a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. Barclays raised their target price on shares of Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Finally, Cowen lowered shares of Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $406.60.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.